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Abstract
Background: Patients with thymoma with immunodeficiency (TWI)/Good’s syndrome characteristically have
evidence of combined immunodeficiency including low or absent B-cells, hypogammaglobulinemia and defects in
T-cell mediated immunity. These patients can present with common or opportunistic infections.
Case presentation: A 54-year-old female was diagnosed with cerebral toxoplasmosis. This occurred on a
background of metastatic thymoma previously treated with chemotherapy and myasthenia gravis (MG) treated with
mycophenolate mofetil, monthly intravenous immunoglobulin (IVIG) and pyridostigmine. She reported recurrent
herpes zoster infection. The patient had clinical and radiological progression of cerebral infection despite
completing standard induction and maintenance therapy with sulfadiazine and pyrimethamine. Investigations
found a complete absence of B-cells and evidence for hypogammaglobulinemia which, together with evidence of
defects in T-cell mediated immunity and thymoma, lead to a diagnosis of TWI/Good’s Syndrome. The patient has
undergone prolonged high-dose therapy for toxoplasmosis and a reduction in immunosuppression with no
evidence of recurrent toxoplasmosis or flare of MG.
Conclusions: TWI/Good’s Syndrome should be suspected in patients with thymoma and recurrent, persistent or
unusual infections. If suspected serum immunoglobulins and lymphocyte subsets should be measured. These
patients may need closer monitoring, higher dose and prolonged treatment of infections, and weaning of
concurrent immunosuppression may be considered.
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Background
Thymoma, the most common tumour of the anterior medi-
astinum, is a rare malignancy of the thymic epithelium of
unknown aetiology affecting males and females with ap-
proximately equal frequency. National Cancer Institute data
from the USA suggests an incidence of 0.13/100 000 [1]
and a peak in the 7th decade. Risk factors for the develop-
ment of thymoma are largely unknown. Unlike other malig-
nancies there is no evidence that common carcinogens
such as tobacco and alcohol increase the risk of thymoma
[1]. Similarly, no association has been shown between
thymoma and other infections including human immuno-
deficiency virus (HIV) or Epstein-Barr virus infection [1].
There does appear to be an underlying genetic risk, with an
increased incidence of thymoma in people of African-
America, Asian and Pacific Island origin [1]. There is scant
evidence suggesting thymoma occurs as a common second
malignancy, including following treatment with ionizing ra-
diation to the thorax [1].
Thymoma has been associated with a number of auto-
immune conditions, with 30 % of patients developing an
autoimmune condition by diagnosis or post-thymectomy
[2]. It has been argued that thymoma-associated auto-
immunity results from the T-cell precursor cells emigrat-
ing from a thymus expressing a dysregulated epithelium,
with low expression of the autoimmune regulatory elem-
ent (AIRE) [3] resulting in auto-reactive peripheral T-
cells. A paucity of bone-marrow dendritic cells has also
been described [3].
Thymoma has been most classically associated with
MG where antibodies directed toward the acetyl choline
receptor (AchR) result in post synaptic membrane de-
struction at the neuromuscular junction. Sixteen percent
of patients with thymoma have a clinical diagnosis of
MG, while an additional 22 % have AChR antibodies in
the absence of clinical signs of disease [4] 15–20 % of
patients with MG have thymic hyperplasia or thymomas.
Interestingly, thymectomy does not provide absolute
protection against developing MG and there have been
reports of patients diagnosed with thymoma without
MG or AChR antibodies, who have undergone thymec-
tomy and have subsequently developed MG over 10 years
later. It has been postulated this is due to the presence
of auto-reactive T-cells already in the periphery. While
MG is the most common thymoma-associated auto-
immune disease other conditions include systemic lupus
erythematousus, syndrome of inappropriate anti-diuretic
hormone, acquired red-cell aplasia and bullous pemphig-
oid [2].
The association of thymoma with immunodeficiency has
been less well appreciated. First described as Good’s Syn-
drome in 1955 [5] this condition was originally described as
thymoma associated with low or absent B-cells, hypogam-
maglobulinaemia and defects in cell-mediated immunity.
More recently this condition has been designated “thym-
oma with immunodeficiency” (TWI) and appears to affect
males and females equally. Here we present the first report
of a case of cerebral toxoplasmosis in a patient with MG
and metastatic thymoma and clinical and laboratory find-
ings consistent with TWI/Good’s Syndrome.
Case report
The patient is a 54-year-old female who presented in
September 2014 with headache, visual disturbance and
right-sided facial weakness. There were no associated
fevers or weight loss. Her past medical history included
MG diagnosed in 1998 when she presented with ptosis
and dysarthria. A thymoma was diagnosed and resected
in 2003 but she subsequently developed pulmonary me-
tastasis in 2011 and was treated with radiotherapy and
chemotherapy including adriamycin, cisplatin and
cyclophosphamide. Her past history also included
hypertension, dyslipidaemia and a previous history of
smoking. Of relevance, our patient contracted primary
varicella zoster at the age of three months and had
three episodes of herpes zoster (shingles) in her fifth
decade. Medications on admission were: mycopheno-
late mofetil (MMF) 1 g PO BD, pyridostigmine 90 mg
PO BD, prednisolone 12 mg PO OD, monthly intraven-
ous immunoglobulin (IVIG) at a dose of 0.4 mg/kg for
MG, atorvastatin 40 mg PO nocte, telmisartan 20 mg
PO OD, multivitamin, calcium and cholecalciferol
1000 IU PO OD.
Blood tests on admission are shown in Table 1. Of
note there was a normal leukocyte count of 7.9 × 109
with low lymphocytes 0.7 × 109/L and monocytes 0.1 ×
109/L. A CT brain showed an irregular contrast enhan-
cing lesion within the left frontal lobe with moderate as-
sociated vasogenic odema. A subsequent MRI confirmed
the solitary solid/cystic rim-enhancing lesion in the left
posterior frontal lobe with moderate vasogenic odema
resulting in a 3.5 cm midline shift (Fig. 1a). In the setting
of known metastatic thymoma this was thought to be
most consistent with an intracranial metastasis. The pa-
tient underwent stereotactic left frontal craniotomy and
excisional biopsy which showed toxoplasmosis on the
basis of histopathology and polymerase chain reaction.
The patient commenced induction therapy for toxo-
plasmosis with sulfadiazine 1 g PO QID, pyrimethamine
75 mg PO OD and calcium folinate 15 mg OD accord-
ing to local guidelines [6]. Her prednisone was increased
to 25 mg PO OD and nystatin 1 ml PO QID was pre-
scribed for oral candidiasis. She was discharged with a
plan for 6 weeks induction course of anti-toxoplasma
treatment and outpatient appointments with Neurology,
Infectious Diseases and Neurosurgery. At review 3 weeks
post-discharge, she complained of nausea, thought to be
secondary to the sulfadiazine. Her medications were
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reduced to sulfadiazine 500 mg PO QID and pyrimeth-
amine 50 mg PO OD.
Four weeks after initial presentation she underwent an
MRI brain for post-neurosurgical follow-up. This re-
vealed multiple new miliary lesions in the cerebral hemi-
spheres bilaterally, which were predominantly cortical
but with involvement of central grey structures including
the right lentiform nucleus and thalamus (Fig. 1b). These
lesions were not present on the initial MRI and were
thought to represent disseminated toxoplasma. The pa-
tient was recommenced on sulfadiazine 1 g PO QID and
pyrimethamine was maintained on 50 mg PO OD. Im-
munological review followed.
Further immunological investigations included flow
cytometric evaluation of lymphocyte subsets which
showed a CD4+ T-cell lymphopenia and complete ab-
sence of B-cells (see Table 1). Serum immunoglobulin
levels showed normal IgG levels (consistent with re-
placement IVIG), low IgM and undetectable IgE and
IgD. Although complicated by immunosuppression with
MMF and treatment with IVIG, it was concluded that
the lack of B-cells, serum immunoglobulins suggestive of
an underlying hypogammaglobulinemia, and T-cell im-
munodeficiency as demonstrated by toxoplasma infec-
tion were all consistent with a diagnosis of TWI/Good’s
Syndrome. The patient received a total of 12 weeks at
induction level therapy for cerebral toxoplasmosis with
sulfadiazine 1 g PO QID and pyrimethamine 50 mg PO
OD. Following this the treatment was reduced to main-
tenance phase with sulfadiazine 1 g PO BD and pyri-
methamine 25 mg OD.
In February 2014, four and a half months after the ini-
tial presentation and 4 weeks after the second reduction
in medications, the patient presented with acute onset
nausea, headache and loss of consciousness. A CT of the
brain showed a new ring-enhancing lesion in the right
temporal lobe. An MRI of the brain confirmed the ring
enhancing lesion in the right temporal lobe and the dif-
fuse miliary nodules present in the previous MRI
(Fig. 1c). These signs were considered to be consistent
with persistent and progressive cerebral toxoplasmosis.
She was recommenced on the induction dose of sulfa-
diazine 1 g PO QID and pyrimethamine 75 mg in
addition to treatment intensification with atovaquone
750 mg PO BD. A cryptococcal antigen was negative as
was HIV antigen/antibody screening. A CT of the chest
showed stable anterior mediastinal and right sided
pleural disease extending to the thoracic vertebrae exit
foramen at the 9/10 level, with no evidence of new me-
tastases (Fig. 2).
Two weeks following discharge a decision was made
to withhold the MMF in order to promote cell-mediated
immunity to the toxoplasma. Lymphocyte subsets re-
peated on multiple occasions consistently showed a
Table 1 Investigations at initial presentation and subsequent
follow-up. Abnormal results are shown in bold. N/A = not
available
Analyte Value Reference Range




Urea 4.8 3–8 mmol/L
Creatinine 72 50-90micromol/L
Bilirubin 16 <21micromol/L
Albumin 37 38–48 g/L





WCC 7.9 4–10 × 109/L
Hb 143 120–150 g/L
Platelets 300 150–400 × 109/L
Neutrophils 7 2–7 × 109/L
Lymphocytes 0.7 1–3 ×109/L
Monocytes 0.1 0.2–1 ×109/L
Eosinophils 0 0.0–0.1 ×109/L
Basophils 0 N/A
Cryptococcal antigen Negative N/A
HIV-1/2 Ag/Ab test Negative N/A
IgG 11.1 6.39–15.6 g/L
IgA 0.73 0.7–3.12 g/L
IgM 0.47 0.5–3 g/L
IgD <0.01 0.01–0.14 g/L
IgE <2kU/L 0–120kU/L
CD3+ T-cell 0.81 × 10^9 1.2–2.7 × 109
CD3 + T-cell (%) 90 % 58–85 %
CD19+ B-cell 0 4–19 %
CD19+ B-cell (%) 0 0.05–0.41 × 109/L
CD4+ T-cell 0.38 × 10^9 0.4–1.32 × 109/L
CD4+ T-cell (%) 42 31–58 %
CD8+ T-cell 0.41 × 10^9 0.22–0.74 × 109/L
CD8 + T-cell (%) 46 % 11–37 %
CD16/56+ NK Cell 10 × 10^9 N/A
CD16/56+ NK Cell (%) 11 N/A
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complete absence of B-cells with fluctuating levels of
CD4+ T-cells with a range 280–1100 × 109/L. At the
time of writing the patient remains stable on induction-
dose sulfadiazine and pyrimethamine together with ato-
vaquone therapy for toxoplasmosis, with MMF being
withheld. The measureable cerebral lesions have reduced
in size on MRI assessment and the miliary lesions have
resolved. Her MG is stable and there have been no signs
of progression of her metastatic thymoma. She is receiv-
ing localised radiotherapy to prevent nerve root and/or
spinal cord compression at the thoracic 9/10 level, and
continues to attend regular Neurology, Infectious Dis-
ease and Immunology outpatient clinics.
Discussion
TWI/Good’s Syndrome is associated with low or absent
B-cells, hypogammaglobulinaemia and defects in cell-
mediated immunity but the mechanism of the immuno-
deficiency largely remains undetermined [7]. Indeed as
late as 2005 this syndrome was considered a subset of
the common variable immunodeficiency (CVID). It is
postulated that the neoplastic thymic epithelium be-
comes disordered in TWI/Good’s Syndrome and results
in a failure of thymic selection processes which may play
a role in the associated T-cell deficiencies. We recently
reported a case of recurrent thymoma where the precur-
sor T-cell infiltrate was monoclonal [8], raising the pos-
sibility that T-cells generated in thymomas have a
restricted T-cell receptor repertoire, that may contribute
to immunodeficiency. How TWI/Good’s Syndrome re-
sults in hypoproduction of B-cells and hypogammaglo-
bulinemia is not well understood. It is postulated that
this may be the result of autoimmune T-cell destruction
of B-cells or aberrant regulatory T-cell function. Similar
to MG, immunological abnormalities in TWI/Good’s
Syndrome are not corrected by thymectomy.
TWI/Good’s Syndrome most commonly presents be-
tween the ages of 40-70years and 47 % of reported world-
Fig. 1 Progressive cerebral toxoplasmosis on interval neuroimaging. Serial magnetic resonance imaging (MRI) of the brain using sagittal T1 weighted
images. At initial presentation there was (a) a solitary rim-enhancing lesion in the left posterior frontal lobe with moderate surrounding vasogenic
odema and a 3.5 cm midline shift to the right. The patient had 4 weeks of therapy with oral sulfadiazine and pyrimethamine. Follow-up imaging
showed (b) a persistent lesion in the left posterior frontal lobe as well as new miliary lesions in the cerebral hemispheres bilaterally and involvement of
central grey structures including the right lentiform nucleus and thalamus. These findings were most consistent with disseminated toxoplasmosis. Four
and a half months after the initial presentation and 4 weeks after a reduction to maintenance therapy the patient represented with nausea, headache
and loss of consciousness and imaging showed (c) a new ring enhancing lesion in the right temporal lobe and persistent diffuse military nodules
a b
Fig. 2 Metastatic thymoma on Computer Tomography (CT) of the chest. Evidence of metastatic thymoma at during follow-up as shown by (a)
anterior mediastinal mass and (b) right sided pleural deposit
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wide cases have been reported from Europe. In the largest
systematic review in this area, Kelesidis and Yang reported
on the clinical laboratory and immunologic findings of 152
cases of TWI/Good’s Syndrome [7]. Patients presented with
bacterial, viral, fungal and protozoan infections. The most
common bacterial infections were recurrent sinopulmonary
and other lung infections, bacteraemia and bacterial diar-
rhoea. The most common viral infections were herpes
simplex virus and human herpes virus (HHV)-8. Candida
infections were common and nine patients had the oppor-
tunistic pneumocystis jirovecii pneumonia (PJP). Of the
parasitic infections giardia was the most common. There
was one case-report of babesia microtii and one case of
ocular toxoplasma [9].
In the same series of patients with TWI/Good’s
Syndrome, all patients had an autoimmune condition with
pure red cell aplasia being the most common (34.8 %)
followed by MG (15.7 %) and oral lichen planus (12.4 %)
[7]. In regards to abnormal laboratory findings all patients
had hypogammaglobulinemia with the majority also dis-
playing low or absent B-cells (87 %), anaemia (85 %) or
CD4 +T-cell lymphopenia <360cells/μL (73 %) [7].
This case demonstrates the importance of considering
immunological investigations in patients with thymoma
who present with unusual infections, the difficulty in
making a diagnosis of TWI/Good’s Syndrome and the
complexity of clinical decision making in such patients.
Our patient was a typical age for a patient with TWI/
Good’s Syndrome. Her thymoma is notable for the fact
that it had metastasised and there is no published data
on whether the incidence of TWI/ Good’s Syndrome is
higher in patients with metastatic thymoma.
In terms of making the diagnosis of TWI/Good’s Syn-
drome the pivotal finding in this case was a complete
absence of B-cells. While our patient additionally had
evidence of hypogammaglobulinemia, this finding was
difficult to interpret due to monthly IVIG for MG. Add-
itionally, the diagnosis of both cerebral toxoplasmosis
and the three episodes of shingles in the previous 4 years
provide evidence of impaired cell-mediated immunity.
While it could be argued that the hypogammaglobuli-
neamia and defects in cellular immunity could be related
to the past history of metastatic thymoma, previous
treatment with systemic chemotherapy and ongoing
MMF, this does not account for the consistent finding of
a complete absence of B-cells in this case which is strik-
ing and helps to confirm the diagnosis of TWI/Good’s
Syndrome. The only other feasible explanation would be
previous treatment with B-cell depletion therapy e.g. Ri-
tuximab which the patient had not received.
This case also illustrates the difficulty in clinical deci-
sion making regarding such patients. Our patient dem-
onstrated progressive cerebral toxoplasmosis even when
a standard 12 week induction therapy schedule was
completed. While there is no international accepted
gold-standard of treatment for cerebral toxoplasmosis,
the combination of sulfadiazine and pyrimethamine has
been shown to be as effective as other commonly used
regimens such as pyrimethamine and clarithromycin, or
trimethoprim-sulfamethoxazole with a cure rate of ap-
proximately 50 % [10]. The decision to add atovaquone
as an additional antimicrobial had to be weighed against
risks of patient tolerability and drug toxicity. The more
difficult decision was that to withhold the MMF im-
munosuppression to aid cell-mediated immunity, a deci-
sion that risked relapse of MG which fortunately has not
occurred. The patient remains on long-term high dose
anti-toxoplasma treatment. There is little data to guide
decisions on duration of treatment and ongoing deci-
sions will have to be made on balance by the treating
teams involved.
Conclusions
To our knowledge this is the first report of cerebral
toxoplasmosis in a patient with TWI/Good’s Syndrome.
This case along with other work demonstrates the im-
portance of undertaking immunological investigations in
patients who have thymoma and infections. This should
include serum immunoglobulins, lymphocyte subsets
and IgG antibodies to toxoplasma and CMV in patients
with confirmed TWI/Good’s Syndrome. Patients with
hypogammaglobulinaemia should receive replacement
IVIG and those with CD4 T-cells counts <200cells/μL
should receive PJP prophylaxis. Additionally, live vac-
cines pose a significant threat to patients with TWI/
Good’s Syndrome and should be avoided where possible.
Unfortunately the prognosis of patients with TWI/
Good’s Syndrome appears to be worse than other im-
munodeficiencies with one single centre study finding
the 10-year survival for patients with CVID being 93 %
but only 33 % in patients with TWI/Good’s Syndrome
[11]. It is hoped that further recognition and aggressive
management of patients with TWI/Good’s Syndrome
along with a growing understanding of this condition
will improve the overall survival.
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